DOCSLIB.ORG

The Management of Urinary and Male Genital Tract Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Management of Urinary and Male Genital Tract Infections Guidelines on The Management of Urinary and Male Genital Tract Infections K.G. Naber (Chairman), M.C. Bishop, T.E. Bjerklund-Johansen, H. Botto, M. Çek, M. Grabe, B. Lobel, J. Palou, P. Tenke © European Association of Urology 2006 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Pathogenesis of urinary tract infections 7 1.2 Microbiological and other laboratory findings 7 1.3 Classification of urinary and male genital infections 8 1.4 Aim of guidelines 8 1.5 Methods 9 1.6 Level of evidence and grade of guidline recommendation 9 1.7 References 9 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 11 2.1 Summary and Recommendations 11 2.1.1 Definition 11 2.1.2 Aetiological spectrum 11 2.1.3 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 11 2.1.4 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 12 2.1.5 Recurrent (uncomplicated) UTIs in women 12 2.1.6 UTIs in pregnancy 12 2.1.7 UTIs in post-menopausal women 12 2.1.8 Acute uncomplicated UTIs in young men 13 2.1.9 Asymptomatic bacteriuria 13 2.2 Background 13 2.3 Definition 13 2.4 Aetiological spectrum 14 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 14 2.5.1 Incidence, risk factors, morbidity 14 2.5.2 Diagnosis 14 2.5.3 Treatment 15 2.5.4 Post-treatment follow-up 19 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 19 2.6.1 Diagnosis 19 2.6.2 Treatment 20 2.6.3 Post-treatment follow-up 22 2.7 Recurrent (uncomplicated) UTIs in women 22 2.7.1 Background 22 2.7.2 Prophylactic antimicrobial regimens 23 2.7.3 Alternative prophylactic methods 25 2.8 UTIs in pregnancy 26 2.8.1 Epidemiology 26 2.8.2 Asymptomatic bacteriuria 26 2.8.3 Acute cystitis during pregnancy 27 2.8.4 Acute pyelonephritis in pregnancy 27 2.9 UTIs in postmenopausal women 27 2.10 Acute uncomplicated UTIs in young men 28 2.10.1 Pathogenesis and risk factors 28 2.10.2 Diagnosis 28 2.10.3 Treatment 28 2.11 Asymptomatic bacteriuria 29 2.12 References 29 3. URINARY TRACT INFECTIONS IN CHILDREN 40 3.1 Summary and recommendations 40 3.2 Background 40 3.3 Aetiology 41 3.4 Pathogenesis and risk factors 41 3.5 Signs and symptoms 41 3.6 Classification 41 3.6.1 Severe UTI 42 3.6.2 Simple UTI 42 2 MARCH 2006 3.7 Diagnosis 42 3.7.1 Physical examination 42 3.7.2 Laboratory tests 42 3.7.2.1 Collection of urine 42 3.7.2.1.1 Suprapubic bladder aspiration 42 3.7.2.1.2 Bladder catheterization 42 3.7.2.1.3 Plastic bag attached to the genitalia 42 3.7.2.2 Quantification of bacteriuria 42 3.7.2.3 Other biochemical markers 43 3.7.2.3.1 Nitrite 43 3.7.2.3.2 Leucocyte esterase 43 3.7.2.3.3 C-reactive protein 43 3.7.2.3.4 Urinary N-acetyl-ß-glucosaminidase 44 3.7.2.3.5 Interleukin-6 44 3.7.3 Imaging of the urinary tract 44 3.7.3.1 Ultrasonography 44 3.7.3.2 Radionuclide studies 44 3.7.3.3 Cystourethrography 44 3.7.3.3.1 Conventional voiding cystourethrography 44 3.7.3.3.2 Radionuclide cystography (indirect) 44 3.7.3.3.3 Cystosonography 45 3.7.3.4 Additional imaging 45 3.7.3.5 Urodynamic evaluation 45 3.8 Schedule of investigation 45 3.9 Treatment 45 3.9.1 Severe UTIs 45 3.9.2 Simple UTIs 46 3.9.3 Prophylaxis 46 3.10 Acknowledgement 47 3.11 References 47 4. UTIs IN RENAL INSUFFICIENCY, TRANSPLANT RECIPIENTS, DIABETES MELLITUS 52 AND IMMUNOSUPRESSION 4.1 Summary 52 4.1.1 Acute effects of UTI on the kidney 52 4.1.2 Chronic renal disease and UTI 52 4.1.2.1 Adult polycystic kidney disease (APCKD) 53 4.1.2.2 Calculi and UTI 53 4.1.2.3 Obstruction and UTI 53 4.1.3 UTI in renal transplantation and immunosuppression 53 4.1.4 Antibiotic treatment for UTI in renal insufficiency and after renal transplantation 53 4.2 Background 53 4.3 Acute effects of a UTI on the kidney 53 4.3.1 Vesicoureteric and intrarenal reflux 53 4.3.2 Obstructive neuropathy 54 4.3.3 Renal effects of severe UTI 54 4.3.4 Acute effects of UTI on the normal kidney 54 4.3.5 Renal scarring 55 4.3.6 Specific conditions in which an acute UTI causes renal damage 55 4.3.6.1 Diabetes mellitus 55 4.3.6.2 Tuberculosis 56 4.4 Chronic renal disease and UTI 56 4.4.1 Adult dominant polycystic kidney disease (ADPK) 56 4.4.2 Renal calculi 56 4.5 UTI in renal transplantation 57 4.5.1 Donor organ infection 57 4.5.2 Graft failure 57 4.5.3 Kidney and whole-organ pancreas transplantation 57 4.6 Antibiotic therapy in renal failure/transplantation 58 4.6.1 Treatment of UTI in renal transplant recipients 58 MARCH 2006 3 4.6.2 Fungal infections 59 4.6.3 Schistosomiasis 59 4.7 Immunosuppression 59 4.7.1 HIV infection 59 4.7.2 Viral and fungal infections 59 4.8 References 59 4.8.1 Further reading 63 5. COMPLICATED UTIs DUE TO UROLOGICAL DISORDERS 64 5.1 Summary and recommendations 64 5.2 Definitions and classification 64 5.2.1 Clinical presentation 65 5.2.2 Urine cultures 65 5.3 Microbiology 65 5.3.1 Spectrum and antibiotic resistance 65 5.3.2 Complicated UTIs associated with urinary stones 65 5.3.3 Complicated UTIs associated with urinary catheters 65 5.4 Treatment 66 5.4.1 General principles 66 5.4.2 Choice of antibiotics 66 5.4.3 Duration of antibiotic therapy 66 5.4.4 Complicated UTIs associated with urinary stones 67 5.4.5 Complicated UTIs associated with indwelling catheters 67 5.4.6 Complicated UTIs in spinal-cord injured patients 67 5.4.7 Follow-up after treatment 67 5.5 Conclusions 67 5.6 References 68 6. CATHETER-ASSOCIATED UTIs 70 6.1 Summary and recommendations 70 6.2 Background 70 6.3 Risk of bacteriuria 70 6.4 Pathogenesis 71 6.4.1 At time of catheter insertion 71 6.4.2 After catheter insertion 71 6.4.3 Biofilm infection 71 6.5 Methods of catheterization and risk of UTI 71 6.5.1 Single catheterization - ‘in-out’ 71 6.5.2 Short-term catheterization 71 6.5.3 Long-term catheterization 72 6.6 Alternative methods of urinary drainage 72 6.6.1 Intermittent catheterization 72 6.6.2 Suprapubic catheterization 73 6.6.3 Condom catheters 73 6.6.4 Urethral stents/prostheses 73 6.6.5 Urinary diversion 73 6.7 Prevention of catheter-associated bacteriuria 73 6.7.1 Catheter care 73 6.7.2 Additional methods of prevention 73 6.8 Treatment 74 6.8.1 Treatment of asymptomatic bacteriuria 74 6.8.2 Treatment of symptomatic UTI 74 6.9 Prevention of cross-infection 74 6.10 References 75 7. SEPSIS IN UROLOGY (UROSEPSIS) 82 7.1 Summary and recommendations 82 7.2 Background 83 7.3 Definition and clinical manifestation of sepsis in urology 83 7.4 Physiology and biochemical markers 84 4 MARCH 2006 7.4.1 Cytokines as markers of the septic response 84 7.4.2 Procalcitonin is a potential marker of sepsis 84 7.5 Prevention 84 7.5.1 Preventive measures of proven or probable efficacy 84 7.5.2 Appropriate peri-operative antimicrobial prophylaxis 85 7.5.3 Preventive measures of debatable efficacy 85 7.5.4 Ineffective or counterproductive measures 85 7.6 Treatment 85 7.6.1 Relief of obstruction 85 7.6.2 Antimicrobial therapy 85 7.6.3 Adjunctive measures 85 7.7 Conclusion 85 7.8 Acknowledgement 86 7.9 References 86 8. URETHRITIS 87 8.1 Definition 87 8.2 Epidemiology 87 8.3 Pathogens 87 8.4 Route of infection and pathogenesis 87 8.5 Clinical course 88 8.6 Diagnosis 88 8.7 Therapy 88 8.8 Prevention 88 8.9 References 88 9. PROSTATITIS AND CHRONIC PELVIC PAIN SYNDROME 89 9.1 Summary and recommendations 89 9.2 Introduction and definition 90 9.3 Diagnosis 90 9.3.1 History and symptoms 90 9.3.1.1 Symptom questionnaires 90 9.3.2 Clinical findings 90 9.3.3 Urine cultures and expressed prostatic secretion 91 9.3.4 Perineal biopsy 91 9.3.5 Other tests 91 9.3.6 Classification systems 92 9.3.7 Diagnostic evaluation 92 9.3.8 Additional investigations 92 9.4 Treatment 93 9.4.1 Antibiotics 93 9.4.2 Antibiotics and α-blockers in combination therapy 93 9.4.3 Other oral medication 94 9.4.4 Intraprostatic injection of antibiotics 94 9.4.5 Surgery 94 9.4.6 Other treatment forms 95 9.5 References 95 10. EPIDIDYMITIS AND ORCHITIS 98 10.1 Definition and classification 98 10.2 Incidence and prevalence 99 10.3 Morbidity 99 10.4 Pathogenesis and pathology 99 10.5 Diagnosis 99 10.5.1 Differential diagnosis 99 10.6 Treatment 99 10.7 References 100 11. PERI-OPERATIVE ANTIBACTERIAL PROPHYLAXIS IN UROLOGY 100 11.1 Summary 100 MARCH 2006 5 11.2 Introduction 101 11.3 Goals of peri-operative antibacterial prophylaxis 101 11.4 Risk factors 102 11.5 Principles of antibiotic prophylaxis 103 11.5.1 Timing 103 11.5.2 Route of administration 103 11.5.3 Duration of the regimen 103 11.5.4 Choice of antibiotics 103 11.6 Prophylactic regimens in defined procedures 103 11.6.1 Diagnostic procedures 105 11.6.2 Endo-urological treatment procedures 105 11.6.3 Laparoscopic surgery 105 11.6.4 Open urological operations without bowel segment with or without 105 opening of the urinary tract 11.6.5 Open urological operations with bowel segment 105 11.6.6 Post-operative drainage of the urinary tract 105 11.6.7 Implant of prosthetic devices 105 11.7 References 107 12.
Load more

Recommended publications
  • Orally Active Esters of Cephalosporin Antibiotics. Ii
    VOL. XXXII NO. 11 THE JOURNAL OF ANTIBIOTICS 1155 ORALLY ACTIVE ESTERS OF CEPHALOSPORIN ANTIBIOTICS. II SYNTHESIS AND BIOLOGICAL PROPERTIES OF THE ACETOXYMETHYL ESTER OF CEFAMANDOLE WALTER E. WRIGHT, WILLIAM J. WHEELER, VERLE D. LINE, JUDITH ANN FROGGE' and DON R. FINLEY Lilly Research Laboratories, Eli Lilly and Company Indianapolis, Indiana 46206, U.S.A. (Received for publication August 29, 1979) The synthesis of the acetoxymethyl (AOM) ester of cefamandole (CM) is described. The sparingly soluble ester is shown to be well absorbed orally by mice, but only when administered in solution in a partially non-aqueous vehicle, 50°o propylene glycol. Neither the ester in aqueous suspension nor the sodium salt of CM in solution is well absorbed orally. The rate of oral absorption of the ester from solution is very rapid as shown by the early peak time and shape of the plasma level curve. Oral bioavailability from solution is at least 60% and is ap- parently limited only by hydrolysis or precipitation of a variable portion of the ester dose in the intestinal lumen prior to absorption. Esterification of the carboxyl group of penicillins and cephalosporins can result in significant improvement in the oral absorption of the parent drug. Pivampicillin1), bacampicillin2) and talampicil- lin3J are examples of such successful penicillin derivatives, and the acetoxymethyl ester of cephaloglycin4 and other cephalosporin derivatives') illustrate the applicability of this pro-drug principle to cephalo- sporins. Although the intact esters are biologically inactive, they can be hydrolyzed to the active parent drug either during passage through the intestinal wall or after absorption has occurred6).
    [Show full text]
  • Guidelines on Urinary and Male Genital Tract Infections
    European Association of Urology GUIDELINES ON URINARY AND MALE GENITAL TRACT INFECTIONS K.G. Naber, B. Bergman, M.C. Bishop, T.E. Bjerklund Johansen, H. Botto, B. Lobel, F. Jimenez Cruz, F.P. Selvaggi TABLE OF CONTENTS PAGE 1. INTRODUCTION 5 1.1 Classification 5 1.2 References 6 2. UNCOMPLICATED UTIS IN ADULTS 7 2.1 Summary 7 2.2 Background 8 2.3 Definition 8 2.4 Aetiological spectrum 9 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 9 2.5.1 Diagnosis 9 2.5.2 Treatment 10 2.5.3 Post-treatment follow-up 11 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 11 2.6.1 Diagnosis 11 2.6.2 Treatment 12 2.6.3 Post-treatment follow-up 12 2.7 Recurrent (uncomplicated) UTIs in women 13 2.7.1 Background 13 2.7.2 Prophylactic antimicrobial regimens 13 2.7.3 Alternative prophylactic methods 14 2.8 UTIs in pregnancy 14 2.8.1 Epidemiology 14 2.8.2 Asymptomatic bacteriuria 15 2.8.3 Acute cystitis during pregnancy 15 2.8.4 Acute pyelonephritis during pregnancy 15 2.9 UTIs in post-menopausal women 15 2.10 Acute uncomplicated UTIs in young men 16 2.10.1 Pathogenesis and risk factors 16 2.10.2 Diagnosis 16 2.10.3 Treatment 16 2.11 References 16 3. UTIs IN CHILDREN 20 3.1 Summary 20 3.2 Background 20 3.3 Aetiology 20 3.4 Pathogenesis 20 3.5 Signs and symptoms 21 3.5.1 New-borns 21 3.5.2 Children < 6 months of age 21 3.5.3 Pre-school children (2-6 years of age) 21 3.5.4 School-children and adolescents 21 3.5.5 Severity of a UTI 21 3.5.6 Severe UTIs 21 3.5.7 Simple UTIs 21 3.5.8 Epididymo orchitis 22 3.6 Diagnosis 22 3.6.1 Physical examination 22 3.6.2 Laboratory tests 22 3.6.3 Imaging of the urinary tract 23 3.7 Schedule of investigation 24 3.8 Treatment 24 3.8.1 Severe UTIs 25 3.8.2 Simple UTIs 25 3.9 References 26 4.
    [Show full text]
  • Association of GUTB and Tubercular Inguinal Lymphadenopathy - a Rare Co-Occurrence
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 15, Issue 7 Ver. I (July 2016), PP 109-111 www.iosrjournals.org Association of GUTB and Tubercular inguinal lymphadenopathy - A rare co-occurrence. 1Hemant Kamal, 2Dr. Kirti Kshetrapal, 3Dr. Hans Raj Ranga 1Professor, Department of Urology & reconstructive surgery, PGIMS Rohtak-124001 (Haryana) Mobile- 9215650614 2Prof. Anaesthesia PGIMS Rohtak, 3Associate Prof. Surgery PGIMS Rohtak. Abstract : Here we present a rare combination of GUTB with B/L inguinal lymphadenopathy in a 55y old male patient presented with pain right flank , fever & significant weight loss for the last 3 months. Per abdomen examination revealed non-tender vague lump in right lumber region about 5x4cm dimensions , with B/L inguinal lymphadenopathy, firm, matted . Investigations revealed low haemoglobin count, high leucocytic & ESR count , urine for AFB was positive and ultrasound revealed small right renal & psoas abscess , which on subsequent start of ATT , got resolved and patient was symptomatically improved . I. Introduction Genitourinary tuberculosis (GUTB) is the second most common form of extrapulmonary tuberculosis after lymph node involvement [1]. Most studies in peripheral LNTB have described a female preponderance, while pulmonary TB is more common in adult males [2]. In approximately 28% of patients with GUTB, the involvement is solely genital [3]. However , the combination of GUTB and LNTB is rare condition. Most textbooks mention it only briefly. This report aims to present a case of GUTB with LNTB in a single patient. II. Case Report 55y male with no comorbidities , having pain right flank & fever X 3months.
    [Show full text]
  • "Egg-Meat-Juice
    dramatic ones fail. The practice of medicine is the per cent.) after the use of sulphuric acid only (25 study of life, and life is composed of little things, and per cent.), and 2 (10 per cent.) after counterstaining. these little things we cannot despise. It was a favorite Smears from the anterior urethra (fossa navicu- saying with the late Professor von Leyden: "For the laris) were made by Young and Churchman2 in 24 patient there are no small things." patients and smegma bacilli found in 11 (46 per cent.), 323 Geary Street. while of 6 patients, smegma bacilli were found in the urine of 5. The urine in the bladder at necropsy, or smears from the bladder wall, were negative in 50 THE SIGNIFICANCE OF TUBERCLE BACILLI cases. The posterior urethra was negative for smegma IN THE URINE bacilli in the 6 cases examined. This work led Young and Churchman2 to advise thorough cleansing of the LAWRASON BROWN, M.D. penis and rinsing with large quantities of water, as SARANAC LAKE, N. Y. well as careful irrigation of the anterior urethra. The The of tubercle bacilli in the urine urine they say should be passed in three glasses and significance may in or may not be grave. I shall consider it first, from the only the third used examination for tubercle bacilli. point of view of discovery of tubercle bacilli in the This technic, they believe, will fully exclude all routine examination of the urine of tuberculous smegma bacilli from the urine and acid- and alcohol- patients; and, secondly, from that of finding tubercle fast bacilli present can be considered tubercle bacilli.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • JMSCR Vol||05||Issue||04||Page 21191-21198||April 2017
    JMSCR Vol||05||Issue||04||Page 21191-21198||April 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.230 Tuberculous Otitis Media: A Prospective Study Authors Dr Sudhir S Kadam1, Dr Geeta S Kadam2, Dr Jaydeep Pol3, Dr Sunil Khot4 1Associate Professor, Department of ENT, Government Medical College Miraj, Maharashrta 2Consulting Pathologist, Yashashri ENT hospital, Miraj, Maharashtra 3Consulting Pathologist, Deep Laboratory, Miraj 4Assistant Professor, Department of ENT, Government Medical College Miraj, Maharashrta Corresponding Author Dr Geeta S Kadam Consulting Pathologist, Yashashri ENT hospital, Miraj, Maharashtra Abstarct Background: Tuberculosis is a chronic granulomatous disease that can affect any part of the body. Being endemic in India tuberculosis must be included in the differential diagnosis of chronic otitis media not responding to usual antibiotics. The diagnosis is more likely in the setting of patients on immunosuppressive therapy, patients receiving steroids or patients with past or family history of tuberculosis. In many cases tuberculous otitis media is not diagnosed mainly because it is often not suspected. We conducted this disease to study the tubercular otitis media, its clinical features, examination findings, intra-operative appearance and for knowing up to what extent an early diagnosis and intervention could restore normal hearing in these patients. Aims and Objectives: To study the patients of tubercular otitis media and their clinical presentations, clinical examination, intraoperative findings and incidence of deafness in patients having tubercular otitis media. Material and Methods: This was a multi-centric prospective cohort study comprising of 60 patients who attended ENT department of a medical college and a well known ENT centre situated in an urban area.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Treating Genitourinary and Pharyngeal Gonorrhoea with Single Dose Ceftriaxone
    Genitourin Med: first published as 10.1136/sti.65.1.14 on 1 January 1989. Downloaded from Genitourin Med 1989;65:14-17 Treating genitourinary and pharyngeal gonorrhoea with single dose ceftriaxone J CHRISTOPHERSEN,* A C BOLLERUP,t E FROM,$ J 0 R0NNE-RASMUSSEN,§ K QUITZAUII From the *Department ofDermatovenereology, Gentofte Hospital, Hellerup; the tNeisseria Department, Statens Seruminstitut, Copenhagen; the tDepartment ofDermatovenereology, Marselisborg Hospital, Aarhus; the §Department ofDermatovenereology, Bispebjerg Hospital, Copenhagen; and the IlDepartment ofClinical Research, Roche, Denmark suMMARY The efficacy of ceftriaxone 250 mg given as a single intramuscular dose to treat genitourinary and pharyngeal gonorrhoea is compared with the outcome of the Danish standard treatment for uncomplicated genitourinary gonorrhoea, pivampicillin 1-4 g and probenecid 1 g, both given by mouth. The study comprised 327 patients for whom the diagnosis ofgonorrhoea was made by microscopy of a methylene blue stained smear at their first visit to the clinic and for whom the diagnosis was later confirmed by culture of Neisseria gonorrhoeae. One hundred and seventy patients with genitourinary gonorrhoea (18 with and 152 without concomitant pharyngeal infection) were treated with ceftriaxone. One hundred and fifty seven (17 with and 140 without concomitant pharyngeal infection) were treated with pivampicillin. One week after treatment N gonorrhoeae was isolated from none of 18, 1/152, (1%), 11/17 (65%), and 6/140 (4%) patients, respectively. At a second attendance two weeks after treatment no further treatment failure was found. During the study period, a further 52 patients with pharyngeal infection (with or without concomitant genitourinary infection) that was shown by culture only were treated with a single http://sti.bmj.com/ intramuscular injection of 250 mg ceftriaxone.
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Clinical Pharmacology of Ampicillin in Infants and Children
    Central Journal of Drug Design and Research Bringing Excellence in Open Access Review Article *Corresponding author Gian Maria Pacifici,Associate professorof Pharmacology,via Sant’Andrea 32,56127 Pisa,Italy. Clinical Pharmacology of Email: [email protected] Submitted: 19 April 2021 Accepted: 25 April 2021 Ampicillin in Infants and Published: 27 April 2021 ISSN: 2379-089X Children Copyright © 2021 Pacifici GM Gian Maria Pacifici* OPEN ACCESS Associate professorof Pharmacology, Italy Keywords Abstract • Ampicillin • Dosing Ampicillin is an aminopenicillin and is more active than penicillin G. Ampicillin is destroyed by β-lactamase • Treatment and is co-formulated with sulbactam an inhibitor of β-lactamase. Ampicillin is bactericidal and it is active • Trials against meningococci, Listeria monocytogenes, enterococci, and the co-administration with sulbactam markedly • Placental-transfer expands the spectrum of activity against Haemophilus influenzae, Escherichia coli, Proteus, and Bacillus fragilis. • Breast-milk Ampicillin may be administered intravenously and orally and the intravenous dose is 50 mg twice-daily and • Meningitis thrice-daily in preterm and term infants, respectively. The oral dose in children ranges from 125 to 500 mg 4 times-daily and increases with the chid age. Ampicillin has been found efficacy and safe in infants and children but may cause adverse-effects. In infants, the ampicillin elimination half-life ranges between 2.4 to 5.0 hours and decreases with infant maturation and in children it is about 0.8 hours. Ampicillin interacts with drugs, the treatment and the trials with ampicillin have been extensively studied in infants and children. This antibiotic freely crosses the human placenta but poorly migrates into the breast-milk.
    [Show full text]
  • Indian Journal of Tuberculosis Published Quarterly by the Tuberculosis Association of India Vol
    Registered with the Registrar of Newspapers of India under No. 655/57 Indian Journal of Tuberculosis Published quarterly by the Tuberculosis Association of India Vol. 57 : No. 2 April 2010 Editor-in-Chief Contents R.K. Srivastava EDITORIAL Editors M.M. Singh Expanding DOTS - New Strategies for TB Control? Lalit Kant - D. Behera 63 V.K. Arora Joint Editors ORIGINAL ARTICLES G.R. Khatri D. Behera Detection of circulating free and immune-complexed antigen in pulmonary tuberculosis using cocktail of Associate Editors antibodies to Mycobacterium tuberculosis excretory S.K. Sharma secretory antigens by peroxidase enzyme immunoassay L.S. Chauhan - Anindita Majumdar, Pranita D. Kamble and Ashok Shah B.C. Harinath 67 J.C. Suri V.K. Dhingra Can cord formation in BACTEC MGIT 960 medium be used Assistant Editor as a presumptive method for identification of M. K.K. Chopra tuberculosis complex? - Mugdha Kadam, Anupama Govekar, Shubhada Members Shenai, Meeta Sadani, Asmita Salvi, Anjali Shetty Banerji, D. and Camilla Rodrigues 75 Gupta, K.B. Katiyar, S.K. Randomized, double-blind study on role of low level Katoch, V.M. nitrogen laser therapy in treatment failure tubercular Kumar, Prahlad lymphadenopathy, sinuses and cold abscess Narang, P. - Ashok Bajpai, Nageen Kumar Jain, Sanjay Avashia Narayanan, P.R. and P.K. Gupta 80 Nishi Agarwal Status Report on RNTCP Paramasivan, C.N. 87 Puri, M.M. CASE REPORTS Radhakrishna, S. Raghunath, D. Pelvic Tuberculosis continues to be a disease of dilemma - Rai, S.P. Case series Rajendra Prasad - S. Chhabra, K. Saharan and D. Pohane 90 Sarin, Rohit Vijayan, V.K. Hypertrophic Tuberculosis of Vulva - A rare presentation of Wares, D.F.
    [Show full text]
  • European Patent Office
    (19) & (11) EP 2 177 209 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 21.04.2010 Bulletin 2010/16 A61K 9/08 (2006.01) A61K 31/4709 (2006.01) A61P 31/04 (2006.01) (21) Application number: 08166910.3 (22) Date of filing: 17.10.2008 (84) Designated Contracting States: • Santos, Benjamin AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08014, Barcelona (ES) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Raga, Manuel RO SE SI SK TR 08024, Barcelona (ES) Designated Extension States: • Otero, Francisco AL BA MK RS 15865, Pedrouzos, Brion (A Coruna) (ES) • Tarruella, Marta (71) Applicant: Ferrer Internacional, S.A. 25214, Santa Fe d’Oluges (Lleida) (ES) 08028 Barcelona (ES) (74) Representative: Reitstötter - Kinzebach (72) Inventors: Patentanwälte • Tarrago, Cristina Sternwartstrasse 4 08950, Esplugues del Llobregat (ES) 81679 München (DE) (54) Intravenous solutions and uses (57) The invention relates to intravenous solutions comprising a desfluoroquinolone compound for use in bacterial infections, and processes for their preparation. EP 2 177 209 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 177 209 A1 Description [0001] The present invention relates to intravenous solutions comprising a desfluoroquinolone compound for use in bacterial infections caused by various bacterial species, and processes for their preparation. 5 [0002] Desfluoroquinolone compound of formula (I) was firstly disclosed in US6335447 and equivalent patents. Its chemical name is 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecar- boxylic acid, and the INN ozenoxacin has been assigned by the WHO.
    [Show full text]